spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
Company profile
Ticker
SPRO
Exchange
Website
CEO
Ankit Mahadevia
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Spero Therapeutics, LLC
SEC CIK
Corporate docs
Subsidiaries
New Pharma License Holdings • Spero Cantab, Inc. • Spero Cantab UK Limited • Spero Europe, Ltd. • Spero Legacy STI, Inc. • Spero Potentiator, Inc. • Spero Potentiator PTY LTD • Spero Securities Corporation ...
SPRO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
8-K
Other Events
29 Mar 24
EFFECT
Notice of effectiveness
25 Mar 24
S-3
Shelf registration
15 Mar 24
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Spero Therapeutics Announces Fourth Quarter and Full Year 2023
13 Mar 24
8-K
Departure of Directors or Certain Officers
9 Feb 24
Transcripts
SPRO
Earnings call transcript
2023 Q4
13 Mar 24
SPRO
Earnings call transcript
2023 Q3
13 Nov 23
SPRO
Earnings call transcript
2023 Q2
10 Aug 23
SPRO
Earnings call transcript
2023 Q1
11 May 23
SPRO
Earnings call transcript
2022 Q4
30 Mar 23
SPRO
Earnings call transcript
2022 Q3
15 Nov 22
SPRO
Earnings call transcript
2022 Q2
11 Aug 22
SPRO
Earnings call transcript
2022 Q1
17 May 22
SPRO
Earnings call transcript
2021 Q4
1 Apr 22
SPRO
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
SC 13G
Anson Funds Management LP
14 Feb 24
4
Timothy Keutzer
5 Feb 24
4
Ankit Mahadevia
5 Feb 24
4
TAMARA L JOSEPH
5 Feb 24
4
KAMAL HAMED
5 Feb 24
4
Esther Rajavelu
5 Feb 24
4
Sath Shukla
5 Feb 24
144
Notice of proposed sale of securities
5 Feb 24
4
Kathleen Tregoning
4 Jan 24
4
Esther Rajavelu
15 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 93.83 mm | 93.83 mm | 93.83 mm | 93.83 mm | 93.83 mm | 93.83 mm |
Cash burn (monthly) | (no burn) | (no burn) | 644.67 k | 260.58 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 4.44 mm | 1.80 mm | n/a | n/a |
Cash remaining | n/a | n/a | 89.38 mm | 92.03 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 138.6 | 353.2 | n/a | n/a |
Institutional ownership, Q2 2023
54.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 57 |
Opened positions | 12 |
Closed positions | 3 |
Increased positions | 9 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 19.79 bn |
Total shares | 29.21 mm |
Total puts | 600.00 |
Total calls | 100.00 |
Total put/call ratio | 6.0 |
Largest owners | Shares | Value |
---|---|---|
GSK GSK | 9.19 mm | $18.66 mm |
Anson Funds Management | 3.44 mm | $5.00 bn |
PFE Pfizer | 2.36 mm | $32.98 mm |
Vanguard | 1.53 mm | $2.21 bn |
Atlas Venture Fund IX | 1.38 mm | $22.05 mm |
Atlas Venture Associates IX | 1.35 mm | $1.96 bn |
Atlas Venture Fund X | 1.03 mm | $20.98 mm |
Atlas Venture Life Science Advisors | 1.01 mm | $1.47 bn |
GOOGL Alphabet Inc - Ordinary Shares | 889.98 k | $1.29 bn |
GV 2015 | 889.98 k | $17.26 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Feb 24 | Sath Shukla | Common Stock | Sell | Dispose S | No | Yes | 1.45 | 45,093 | 65.38 k | 1,176,007 |
2 Feb 24 | Mahadevia Ankit | Common Stock | Sell | Dispose S | No | No | 1.37 | 63,795 | 87.40 k | 744,997 |
2 Feb 24 | Kamal Hamed | Common Stock | Sell | Dispose S | No | No | 1.37 | 28,075 | 38.46 k | 788,117 |
2 Feb 24 | Sath Shukla | Common Stock | Sell | Dispose S | No | No | 1.37 | 30,901 | 42.33 k | 1,221,100 |
2 Feb 24 | Joseph Tamara L | Common Stock | Sell | Dispose S | No | No | 1.37 | 30,906 | 42.34 k | 531,615 |
1 Feb 24 | Kamal Hamed | Common Stock | Grant | Acquire A | No | No | 0 | 239,731 | 0.00 | 816,192 |
1 Feb 24 | Esther Rajavelu | Common Stock | Grant | Acquire A | No | No | 0 | 119,866 | 0.00 | 419,866 |
1 Feb 24 | Sath Shukla | Common Stock | Grant | Acquire A | No | No | 0 | 679,501 | 0.00 | 1,252,001 |
1 Feb 24 | Joseph Tamara L | Common Stock | Grant | Acquire A | No | No | 0 | 239,731 | 0.00 | 562,521 |
News
Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics
4 Apr 24
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
14 Mar 24
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
14 Mar 24
Recap: Spero Therapeutics Q4 Earnings
13 Mar 24
Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
13 Mar 24
Press releases
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
14 Mar 24
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
13 Mar 24
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
28 Feb 24
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
26 Feb 24
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 24